Singapore - English - HSA (Health Sciences Authority)

sebia singapore pte ltd - immunology - the alegria® anti-vzv iga is an elisa based test system intended for the quantitative measurement of iga class antibodies against varizella-zoster-virus in human serum or plasma samples. this product is intended for professional in vitro diagnostic use only.

Singapore - English - HSA (Health Sciences Authority)

sebia singapore pte ltd - immunology - the alegria® anti-vzv igg is an elisa based test system intended for the quantitative measurement of igg class antibodies against varizella-zoster-virus in human serum or plasma samples. this product is intended for professional in vitro diagnostic use only.

Singapore - English - HSA (Health Sciences Authority)

sebia singapore pte ltd - immunology - the alegria® anti-vzv igm abs. is an elisa-based test system for the quantitative measurement of igm class antibodies against varizella-zoster-virus in human serum or plasma samples. this product is intended for professional in vitro diagnostic use only. the alegria® anti-vzv igm abs. offers test strips with integrated rheumatoid factor (rf) absorbent.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: dibasic sodium phosphate; sodium chloride; urea; potassium chloride; sucrose; monobasic potassium phosphate; monosodium glutamate monohydrate; hydrolysed gelatin - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; sodium chloride; sucrose; hydrolysed gelatin; dibasic sodium phosphate; monobasic potassium phosphate; potassium chloride; urea - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; monobasic potassium phosphate; urea; sodium chloride; dibasic sodium phosphate; hydrolysed gelatin; potassium chloride; sucrose - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 19400 [pfu] in 0.65 ml - zostavax® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. limitations of use of zostavax: - zostavax is not indicated for the treatment of zoster or postherpetic neuralgia (phn). - zostavax is not indicated for prevention of primary varicella infection (chickenpox). do not administer zostavax to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1} do not administer zostavax to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, aids or other clinical manifestations of infection with human immunodeficiency

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - varicella zoster virus glycoprotein e antigen - powder and suspension for suspension for injection - varicella zoster virus glycoprotein e antigen 50 mcg - zoster, purified antigen - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in: • adults 50 years of age or older; • adults 18 years of age or older at increased risk of hz.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - varicella-zoster virus (live, attenuated) - herpes zoster; immunization - viral vaccines - zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. zostavax is indicated for immunisation of individuals 50 years of age or older.,